NNOX vs. EMBC, TNDM, BBNX, SIBN, AXGN, BVS, AVNS, ZIMV, KIDS, and TMCI
Should you be buying Nano-X Imaging stock or one of its competitors? The main competitors of Nano-X Imaging include Embecta (EMBC), Tandem Diabetes Care (TNDM), Beta Bionics (BBNX), SiBone (SIBN), AxoGen (AXGN), Bioventus (BVS), Avanos Medical (AVNS), ZimVie (ZIMV), OrthoPediatrics (KIDS), and Treace Medical Concepts (TMCI). These companies are all part of the "medical equipment" industry.
Nano-X Imaging vs. Its Competitors
Embecta (NASDAQ:EMBC) and Nano-X Imaging (NASDAQ:NNOX) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.
Embecta has a net margin of 7.58% compared to Nano-X Imaging's net margin of -468.29%. Embecta's return on equity of -23.40% beat Nano-X Imaging's return on equity.
Embecta has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500. Comparatively, Nano-X Imaging has a beta of 1.94, indicating that its stock price is 94% more volatile than the S&P 500.
In the previous week, Embecta had 3 more articles in the media than Nano-X Imaging. MarketBeat recorded 4 mentions for Embecta and 1 mentions for Nano-X Imaging. Embecta's average media sentiment score of 1.24 beat Nano-X Imaging's score of 0.00 indicating that Embecta is being referred to more favorably in the media.
93.8% of Embecta shares are owned by institutional investors. Comparatively, 21.5% of Nano-X Imaging shares are owned by institutional investors. 0.4% of Embecta shares are owned by company insiders. Comparatively, 7.7% of Nano-X Imaging shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Embecta has higher revenue and earnings than Nano-X Imaging. Nano-X Imaging is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.
Embecta currently has a consensus target price of $19.00, indicating a potential upside of 32.20%. Nano-X Imaging has a consensus target price of $8.50, indicating a potential upside of 127.58%. Given Nano-X Imaging's stronger consensus rating and higher probable upside, analysts plainly believe Nano-X Imaging is more favorable than Embecta.
Summary
Embecta beats Nano-X Imaging on 10 of the 17 factors compared between the two stocks.
Get Nano-X Imaging News Delivered to You Automatically
Sign up to receive the latest news and ratings for NNOX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NNOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nano-X Imaging Competitors List
Related Companies and Tools
This page (NASDAQ:NNOX) was last updated on 9/4/2025 by MarketBeat.com Staff
Free NNOX Stock Alerts